Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, et al. Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference. Clin J Am Soc Nephrol. 2008;3:471–80.
Abdelwahab Elhamahmi D, Heilman RL, Smith B, Huskey J, Khamash H, Kaplan B. Early conversion to belatacept in kidney transplant recipients with low glomerular filtration rate. Transplantation. 2018;102(3):478–83.
Abraham WT, Smith SA. Devices in the management of advanced, chronic heart failure. Nat Rev Cardiol. 2013;10:98–110.
Abramowicz D, Cochat P, Claas FH, Heemann U, Pascual J, Dudley C, et al. European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care. Nephrol Dial Transplant. 2015;30:1790–7.
Addis RC, Epstein JA. Induced regeneration--the progress and promise of direct reprogramming for heart repair. Nat Med. 2013;19:829–36.
Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85–118.
Alraies MC, Eckman P. Adult heart transplant: indications and outcomes. J Thorac Dis. 2014;6:1120–8.
American Society of Transplantation Infectious Diseases Guidelines 3rd Edition. March 2013; 13(s4):1–371. Available from: http://onlinelibrary.wiley.com/doi/10.1111/ajt.2013.13.issue-s4/issuetoc (accessed June 2017).
Andrews PA, Burnapp L, Manas D, Bradley JA, Dudley C; British Transplantation Society; et al. Summary of the British Transplantation Society/Renal Association U.K. guidelines for living donor kidney transplantation. Transplantation. 2012;93:666–73.
Andrews PA, Emery VC, Newstead C. Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation. Transplantation. 2011;92:1181–7.
Andrews PA; Standards Committee of the British Transplantation Society. Summary of the British Transplantation Society Guidelines for Management of the Failing Kidney Transplant. Transplantation. 2014;98:1130–3.
Angeli P, Bezinover D, Biancofiore G, Bienholz A, Findlay J, Paugam Burtz C, et al. Acute kidney injury in liver transplant candidates: a position paper on behalf of the Liver Intensive Care Group of Europe. Minerva Anestesiol. 2017;83:88–101.
Assfalg V, Hüser N, van Meel M, Haller B, Rahmel A, de Boer J, et al. High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey. Nephrol Dial Transplant. 2016;31:1515–22.
Augustine JJ, Hricik DE. Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol. 2006;1:1080–9.
Bagshaw SM, Lamontagne F, Joannidis M, Wald R. When to start renal replacement therapy in critically ill patients with acute kidney injury: comment on Living kidney donation and ELAIN. Crit Care. 2016;20:245.
Bamgbola O. A Critical Review of Steroid Immunotherapy in Kidney Transplantation. Int J Immunol Immunother. 2015;2:1.
Batabyal P, Chapman JR, Wong G, Craig JC, Tong A. Clinical practice guidelines on wait-listing for kidney transplantation: Consistent and equitable? Transplantation. 2012;94:703–13.
Bathla L, Langnas A. Chapter 63. Multivisceral Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 697–702. 2014; Wiley Online Library.
Bessede T, Droupy S, Hammoudi Y, Bedretdinova D, Durrbach A, Charpentier B, et al. Surgical prevention and management of vascular complications of kidney transplantation. Transpl Int. 2012;25:994–1001.
Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, Zocrato J, et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology. 2011;53:1570–9.
Bhat M, Al-Busafi S, Deschênes M, Ghali P. Care of the liver transplant patient. Can J Gastroenterol Hepatol. 2014;28:213–9.
Bloom RD, Reese PP. Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol. 2007;18:3031–41.
Bownik H, Saab S. Health-related quality of life after liver transplantation for adult recipients. Liver Transpl. 2009;15 Suppl 2:S42–9.
Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant. 2011;11:2453–62.
Briasoulis A, Inampudi C, Pala M, Asleh R, Alvarez P, Bhama J. Induction immunosuppressive therapy in cardiac transplantation: a systematic review and meta-analysis. Heart Fail Rev. 2018; [Epub ahead of print].
British Transplantation Society. British Transplantation Society Guidelines for the prevention and management of CMV disease after solid organ transplantation. 2011; Available from: https://bts.org.uk/wp-content/uploads/2016/09/14_BTS_CMV_3RDE-1.pdf (accessed June 2017).
British Transplantation Society. UK Guidelines for kidney and pancreas transplantation in patients with HIV. 2015; Available from: https://bts.org.uk/wp-content/uploads/2017/04/02_BTS_Kidney_Pancreas_HIV.pdf (accessed June 2017).
British Transplantation Society and Renal Association. United Kingdom guidelines for living donor kidney transplantation. 2011; Available from: https://bts.org.uk/wp-content/uploads/2016/09/19_BTS_RA_Living_Donor_Kidney-1.pdf (accessed June 2017).
Broumand B. The global registry: hope for the future. Exp Clin Transplant. 2015;13 Suppl 1:4–8.
Budde K, Lehner F, Sommerer C, Reinke P, Arns W, Eisenberger U, et al. Five-year outcomes in kidney transplant patients converted from ciclosporin to everolimus: the randomized ZEUS study. Am J Transplant. 2015;15:119–28.
Casey MJ, Meier-Kriesche HU. Calcineurin inhibitors in kidney transplantation: friend or foe? Curr Opin Nephrol Hypertens. 2011;20:610–5.
Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect Med 2013;3:a015677.
Charlton MR. Sirolimus as a calcineurin inhibitor- and renal-sparing agent: all good things come to those who wait versus spare the nephron, spoil the patient. Liver Transpl. 2013;19(8):787–9.
Charlton MR. Improving long-term outcomes after liver transplantation. Clin Liver Dis. 2014;18:717–30.
Charlton M, Rinella M, Patel D, McCague K, Heimbach J, Watt K. Everolimus is associated with less weight gain than tacrolimus 2 years after liver transplantation: results of a randomized multicenter study. Transplantation. 2017;101(12):2873–82.
Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int. 2014;27(10):1039–49.
Cibrik D, Silva HT Jr, Vathsala A, Lackova E, Cornu-Artis C, Walker RG, et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation. 2013;95:933–42.
Clajus C, Hanke N, Gottlieb J, Stadler M, Weismüller TJ, Strassburg CP, et al. Renal comorbidity after solid organ and stem cell transplantation. Am J Transplant. 2012;12:1691–9.
Collaborative Transplant Study (CTS). 2016; Available from: http://www.ctstransplant.org/ (accessed June 2017).
Collett D, Mumford L, Banner NR, Neuberger J, Watson CJE. Comparison of the incidence of malignancy in recipients of different types of organ: a UK registry audit. Am J Transplant. 2010; 10:1889–96.
Cooper JE, Christians U, Wiseman AC. Everolimus in kidney transplantation. Transpl Res Risk Management. 2011;3:97–112.
Copelan E.A. (2006). Hematopoietic stem-cell transplantation. New Engl J Med. 2006;354:1813–26.
Colvin M, Smith JM, Skeans MA, Edwards LB, Uccellini K, Snyder JJ, et al. OPTN/SRTR 2015 Annual Data Report: Heart. Am J Transplant. 2017;17 Suppl 1:286-356.
Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914–56.
Craig JM, Lee S, Vlahakes GL, Madsen JC. Chapter 58. Heart Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 657–66. 2014; Wiley Online Library.
Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618–28.
Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, et al. Efficacy and safety of de novo or early everolimus with low ciclosporin in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 2010;23:1084–93.
Davis CL, Delmonico FL. Living-donor kidney transplantation: a review of the current practices for the live donor. J Am Soc Nephrol. 2005;16:2098–110.
Davis RD, Hartwig M. Chapter 59. Lung Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 667–73. 2014; Wiley Online Library.
Delanaye P, Weekers L, Dubois BE, Cavalier E, Detry O, Squifflet JP, et al. Outcome of the living kidney donor. Nephrol Dial Transplant. 2012;27:41–50.
Desai R, Neuberger J. Donor transmitted and de novo cancer after liver transplantation. World J Gastroenterol. 2014;20:6170–9.
De Simone P, Carrai P, Coletti L, Ghinolfi D, Petruccelli S, Filipponi F. Modification of immunosuppressive therapy as risk factor for complications after liver transplantation. Best Pract Res Clin Gastroenterol. 2017b;31(2):199–209.
De Simone P, Fagiuoli S, Cescon M, De Carlis L, Tisone G, Volpes R, et al. Use of Everolimus in Liver Transplantation: Recommendations From a Working Group. Transplantation. 2017a;101:239–51.
De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012;12(11):3008–20.
Diaz G, O'Connor M. Cardiovascular and renal complications in patients receiving a solid-organ transplant. Curr Opin Crit Care. 2011;17:382–9.
Dominguez-Gil B, Delmonico FL, Shaheen FA, Matesanz R, O'Connor K, Minina M, et al. The critical pathway for deceased donation: reportable uniformity in the approach to deceased donation. Transplant Int. 2011;24:373–8.
Dudley C, Harden P. Assessment of the Potential Kidney Transplant Recipient. 2011; Available from: https://bts.org.uk/wp-content/uploads/2016/09/10_RA_KidneyRecipient-1.pdf (accessed June 2017).
Dufour M, Dormond-Meuwly A, Demartines N, Dormond O. Targeting the Mammalian Target of Rapamycin (mTOR) in cancer therapy: lessons from past and future perspectives. Cancers (Basel). 2011;3:2478–500.
Dumortier J, Dharancy S, Calmus Y, Duvoux C, Durand F, Salamé E, et al. Use of everolimus in liver transplantation: The French experience. Transplant Rev (Orlando). 2016;30(3):161–70.
Dürr M, Lachmann N, Zukunft B, Schmidt D, Budde K, Brakemeier S. Late conversion to belatacept after kidney transplantation: outcome and prognostic factors. Transplant Proc. 2017;49(8):1747–56.e1.
Einecke G, Reeve J, Halloran PF. Hyalinosis lesions in renal transplant biopsies: time-dependent complexity of interpretation. Am J Transplant. 2017;17:1346–57.
Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, et al; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. New Engl J Med. 2007;357: 2562–75.
EMA. Simulect, basiliximab. October 2009a; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000207/human_med_001054.jsp&mid=WC0b01ac058001d124 (accessed June 2017).
EMA. Zenapax, daclizumab. February 2009b; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000198/human_med_001175.jsp&mid=WC0b01ac058001d124 (accessed June 2017).
European Association for the Study of the Liver (EASL). The burden of liver disease in Europe. 2013; Available from: www.easl.eu/medias/EASLimg/Discover/EU/54ae845caec619f_file.pdf (accessed June 2017).
European Commission. Organs. 2016; Available from: http://ec.europa.eu/health/blood_tissues_organs/organs/index_en.htm (accessed June 2017).
Eurotransplant. Annual Report 2014. 4: Eurotransplant: donation, waiting lists and transplants. Available from: http://www.eurotransplant.org/cms/mediaobject.php?file=ar_2014.pdf (accessed June 2017).
Finkbeiner SR, Freeman JJ, Wieck MM, El-Nachef W, Altheim CH, Tsai YH, et al. Generation of tissue-engineered small intestine using embryonic stem cell-derived human intestinal organoids. Biol Open. 2015;4:1462–72.
Fishbein T. Chapter 62. Intestinal Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 691–6. 2014; Wiley Online Library.
Fischer SA, Lu K; AST Infectious Diseases Community of Practice. Screening of donor and recipient in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):9–21.
Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simnone P, et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus. Follow-up results from a randomized, multicenter study. Transplantation. 2015;99(7):1455–62.
Fisher MB, Mauck RL. Tissue engineering and regenerative medicine: recent innovations and the transition to translation. Tissue Eng Part B Rev. 2013;19:1–13.
Fishman JA; AST Infectious Diseases Community of Practice. Introduction: infection in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S3–6.
Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant. 2008;22:1–15.
Fredericks EM, Zelikovsky N, Aujoulat I, Hames A, Wray J. Post-transplant adjustment--the later years. Pediatr Transplant. 2014;18:675–88.
Friend PJ. Alemtuzumab induction therapy in solid organ transplantation. Transplant Res. 2013;2:S5.
Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med. 2016;375:122–33.
Gentile S, Beauger D, Speyer E, Jouve E, Dussol B, Jacquelinet C, et al. Factors associated with health-related quality of life in renal transplant recipients: results of a national survey in France. Health Qual Life Outcomes. 2013;11:88.
Gibbons N, Nicol D. Surgical techniques in living donor nephrectomy. Nephrology (Carlton). 2010;15:S88–95.
Global Observatory on Donation and Transplantation. Organ donation and transplant activities, 2013. Available from: http://www.transplant-observatory.org/report-2013/ (accessed June 2017).
Gondos A, Döhler B, Brenner H, Opelz G. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation. 2013;95:267–74.
Grams ME, Sang Y, Levey AS, Matsushita K, Ballew S, Chang AR, et al. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med. 2016;374:411–21.
Grant RC, Sandhu L, Dixon PR, Greig PD, Grant DR, McGilvray ID. Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Transplant. 2013;27:140–7.
Green M, Michaels MG. Infections in Pediatric Solid Organ Transplant Recipients. J Pediatric Infect Dis Soc. 2012;1:144–51.
Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud. 2011;8:6–16.
Gruessner RW, Gruessner AC. Pancreas After Islet Transplantation: A First Report of the International Pancreas Transplant Registry. Am J Transplant. 2016;16:688–93.
Hariharan K, Kurtz A, Schmidt-Ott KM. Assembling Kidney Tissues from Cells: The Long Road from Organoids to Organs. Front Cell Dev Biol. 2015;3:70.
Hart A, Gustafson SK, Skeans MA, Stock P, Stewart D, Kasiske BL, et al. OPTN/SRTR 2015 Annual Data Report: Early effects of the new kidney allocation system. Am J Transplant. 2017;17 Suppl 1:543–564.
Hartono C, Muthukumar T, Suthanthiran M. Immunosuppressive drug therapy. Cold Spring Harb Perspect Med. 2013;3:a015487.
Health Quality Ontario. Limbal stem cell transplantation: an evidence-based analysis. Ont Health Technol Assess Ser. 2008;8:1–58.
Health Quality Ontario. Pancreas islet transplantation for patients with type 1 Diabetes Mellitus: A Clinical Evidence Review. Ont Health Technol Assess Ser. 2015;15:1–84.
Health Resources and Services Administration: Blood Cell Transplant. 2015; Transplant Activity Report. Available from: http://bloodcell.transplant.hrsa.gov/research/transplant_data/transplant_activity_report/index.html (accessed April 2016).
Health Resources and Services Administration. Organ Procurement and Transplantation Network. 2016a; Available from: http://optn.transplant.hrsa.gov/ (accessed April 2016).
Health Resources and Services Administration. Organ Procurement and Transplantation Network. Evolution of liver allocation and distribution. 2016b; Available from: https://optn.transplant.hrsa.gov/governance/policy-initiatives/liver-timeline/ (accessed June 2017).
Health Resources and Services Administration. Organ Procurement and Transplantation Network. Kidney Allocation System. 2016c; Available from: https://optn.transplant.hrsa.gov/learn/professional-education/kidney-allocation-system/ (accessed June 2017).
Heemann U, Renders L. State of living kidney donation in Europe. Nephrol Dial Transplant. 2012;27:2166–70.
Hill P, Cross NB, Barnett AN, Palmer SC, Webster AC. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cochrane Database Syst Rev. 2017;1:CD004759.
Hollisaaz MT, Aghanassir M, Lorgard-Dezfuli-Nezad M, Assari S, Hafezie R, Ebrahiminia M. Medical comorbidities after renal transplantation. Transplant Proc. 2007;39:1048–50.
Hu Z, Wang W, Li Z, Ye S, Zheng SS. Recipient outcomes of salvage liver transplantation versus primary liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2012;18:1316–23.
Huh KH, Lee JG, Ha J, Oh CK, Ju MK Kim CD, et al. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial. Nephrol Dial Transplant. 2017;32(8):1415–24.
Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol. 2008;52:587–98.
Ifudu O, Paul HR, Homel P, Friedman EA. Predictive value of functional status for mortality in patients on maintenance hemodialysis. Am J Nephrol. 1998;18:109–16.
ISHLT Monograph Series. Volume 2: Pediatric Heart Transplantation. Canter CE, Kirklin JK (eds). April 2008; Available from: https://www.ishlt.org/publications-resources/monograph-series/monograph-volume-2 (accessed June 2017).
ISHLT Monograph Series. Volume 6: ISHLT Guidelines for the Care of Heart Transplant Recipients. Costanzo MR, Hunt SA, Taylor DO, Kirklin JK (eds). April 2012; Available from: https://www.ishlt.org/publications-resources/monograph-series/monograph-volume-6 (accessed June 2017).
ISHLT Monograph Series. Volume 7: Pediatric Lung Transplantation. Goldfarb S, Benden C, Sweet S, Kirklin JK (eds). April 2013; Available from: https://www.ishlt.org/publications-resources/monograph-series/monograph-volume-7 (accessed June 2017).
Jacobs CL, Gross CR, Messersmith EE, Hong BA, Gillespie BW, Hill-Callahan P, et al. Emotional and financial experiences of kidney donors over the past 50 Years: The RELIVE study. Clin J Am Soc Nephrol. 2015;10:2221–31.
Jeng LB, Lee SG, Soin AS, Lee WC, Suh KS, Joo DJ, et al. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant. 2017; [Epub ahead of print].
Jiang AT, Rowe N, Sener A, Luke P. Simultaneous pancreas-kidney transplantation: The role in the treatment of type 1 diabetes and end-stage renal disease. Can Urol Assoc J. 2014;8:135–8.
Journalist workshop on organ donation and transplantation. Recent facts & figures. November 2014; Available from: http://ec.europa.eu/health/blood_tissues_organs/docs/ev_20141126_factsfigures_en.pdf (accessed June 2017).
Kandaswamy R, Stock PG, Gustafson SK, Skeans MA, Curry MA, Prentice MA, et al. OPTN/SRTR 2015 Annual Data Report: Pancreas. Am J Transplant. 2017;17 Suppl 1:117–173.
Karam VH, Gasquet I, Delvart V, Hiesse C, Dorent R, Danet C, et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation. 2003;76:1699–704.
Karthikeyan V, Karpinski J, Nair RC, Knoll G. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant. 2004;4:262–9.
Karuthu S, Blumberg EA. Common infections in kidney transplant recipients. Clin J Am Soc Nephrol. 2012;7:2058–70.
Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients. Kidney Int. 2010;77:299–311.
Kaufman DB, Odorico JS, Sollinger HW. Chapter 60. Pancreas Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 674–81. 2014; Wiley Online Library.
Keating GM, Lyseng-Williamson KA. Everolimus: a guide to its use in liver transplantation. BioDrugs. 2013;27:407–11.
Kemter E, Wolf E. Pigs pave a way to de novo formation of functional human kidneys. Proc Natl Acad Sci USA. 2015;112:12905–6.
Kern B, Sucher R. Clinical immunosuppression in solid organ and composite tissue allotransplantation. In: Immunosuppression – Role in Health and Diseases. Kapur S, Portela MB (eds). InTech. 2012; Available from: http://www.intechopen.com/books/immunosuppression-role-in-health-and-diseases (accessed June 2017).
Khaja MS, Matsumoto AH, Saad WE. Complications of transplantation. Part 1: renal transplants. Cardiovasc Intervent Radiol. 2014;37:1137–48.
Khalifian S, Grahammer J, Lee WPA, Brandacher G. Stem Cell-based Tolerance Induction in Transplantation. J Stem Cell Res Ther. 2013;S6:003.
Khan A, Nasr P, El-Charabaty E, El-Sayegh S. An insight into the immunologic events and risk assessment in renal transplantation. J Clin Med Res. 2016;8:367–72.
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9:S1–155.
Kim WR, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards EB, et al. OPTN/SRTR 2015 Annual Data Report: Liver. Am J Transplant. 2017;17 Suppl 1:174–251.
Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. 2015;14(7):1055–70.
Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ. 2014;349:g6679.
Kong Y, Wang D, Shang Y, Liang W, Ling X, Guo Z, et al. Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis. PLoS One. 2011;6:e24387.
Koo TY, Yang J. Current progress in ABO-incompatible kidney transplantation. Kidney Res Clin Pract. 2015;34:170–9.
Koomalsingh K, Kobashigawa JA. The future of cardiac transplantation. Ann Cardiothorac Surg. 2018;7(1):135–42.
Kousoulas L, Neipp M, Barg-Hock H, Jackobs S, Strassburg CP, Klempnauer J, et al. Health-related quality of life in adult transplant recipients more than 15 years after orthotopic liver transplantation. Transpl Int. 2008; 21:1052–8.
Kugler C, Gottlieb J, Warnecke G, Schwarz A, Weissenborn K, Barg-Hock H, et al. Health-related quality of life after solid organ transplantation: a prospective, multiorgan cohort study. Transplantation. 2013;96:316–23.
Kwan JM, Hajjiri Z, Metwally A, Finn PW, Perkins DL. Effect of the Obesity Epidemic on Kidney Transplantation: Obesity Is Independent of Diabetes as a Risk Factor for Adverse Renal Transplant Outcomes. PLoS One. 2016;11:e0165712.
Kymionis GD, Mikropoulos DG, Portaliou DM, Boboridis KG, Voudouragkaki IC, Dragoumis ND, et al. New perspectives on lamellar keratoplasty. Adv Ther. 2014;31:494–511.
Lafranca JA, van Bruggen M, Kimenai HJ, Tran TC, Terkivatan T, Betjes MG, et al. Vascular Multiplicity Should Not Be a Contra-Indication for Live Kidney Donation and Transplantation. PLoS One. 2016;11:e0153460.
Langer RM, Hené R, Vitko S, Christiaans M, Tedesco-Silva H Jr, Ciechanowski K, et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int. 2012;25:592–602.
Lao OB, Healey PJ, Perkins JD, Horslen S, Reyes JD, Goldin AB. Outcomes in children after intestinal transplant. Pediatrics. 2010;125:e550–8.
Lee S-G, Moon D-B, Namgoong J-M. Chapter 57. Living Donor Liver Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 639–56. 2014; Wiley Online Library.
Létourneau S, Krieg C, Pantaleo G, Boyman O. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol. 2009;123:758–62.
Liang L, Sheha H, Li J, Tseng SC. Limbal stem cell transplantation: new progresses and challenges. Eye (Lond). 2009;23:1946–53.
Liu J, Liu D, Li J, Zhu L, Zhang C, Lei K, et al. Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2017;12:e0170246.
Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19:3–26.
Magliocca JF, Hanish SI, Page EK, Knechtle SJ. Chapter 56. Liver Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 631–8. 2014; Wiley Online Library.
Manara AR, Murphy PG, O’Callaghan G. Donation after circulatory death. Br J Anaesth 2012;108:i108–21.
Manas D, Burnapp L, Andrews PA. Summary of the British Transplantation Society UK Guidelines for Living Donor Liver Transplantation. Transplantation. 2016;100:1184–90.
Manitpisitkul W, Lee S, Cooper M. Mycophenolic acid agents: is enteric coating the answer? Transpl Res Risk Management. 2011;3:45–53.
Martin JE, Cavanaugh TM, Trumbull L, Bass M, Weber F Jr, Aranda-Michel J, et al. Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients. Clin Transplant. 2008;22:113–9.
Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144–65.
Martins AM, Vunjak-Novakovic G, Reis RL. The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine. Stem Cell Rev. 2014;10:177–90.
Masson P, Henderson L, Chapman JR, Craig JC, Webster AC. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev. 2014;11:CD010699.
Mastoridis S, Martínez-Llordella M, Sanchez-Fueyo A. Biomarkers and immunopathology of tolerance. Curr Opin Organ Transplant. 2016;21:81–7.
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334:693–9.
McCracken KW, Catá EM, Crawford CM, Sinagoga KL, Schumacher M, Rockich BE, et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature. 2014;516:400–4.
Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant. 2016;35:1–23.
Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. J Heart Lung Transplant 2006;25:1024–42.
Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant. 2005;5:2273–80.
Meier-Kriesche HU, Steffen BJ, Chu AH, Loveland JJ, Gordon RD, Morris JA, et al. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant. 2004;4:2058–66.
Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27:2278–87.
Messersmith EE, Gross CR, Beil CA, Gillespie BW, Jacobs C, Taler SJ, et al. Satisfaction with life among living kidney donors: A RELIVE study of long term donor outcomes. Transplantation. 2014;98:1294–300.
Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014;44:1479–503.
Middleton SJ, Pither C, Gao R, Duncan S, Green J, Sharkey L, et al. Adult small intestinal and multivisceral transplantation: lessons through the "retrospecto-scope" at a single UK centre from 1991 to 2013. Transplant Proc. 2014;46:2114–8.
Milliman. 2014 U.S. organ and tissue transplant cost estimates and discussion. December 2014; http://www.milliman.com/uploadedFiles/insight/Research/health-rr/1938HDP_20141230.pdf (accessed April 2018).
Mitta S, Gough SC. Pancreas transplantation a treatment option for people with diabetes. Diabet. Med. 2014;31:512–21.
Mohty M, Bacigalupo A, Saliba F, Zuckermann A, Morelon E, Lebranchu Y. New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity. Drugs. 2014;74:1605–34.
Montero N, Webster AC, Royuela A, Zamora J, Crespo Barrio M, Pascual J. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients. Cochrane Database Syst Rev. 2014;9:CD007669.
Morales JM, Marcén R, del Castillo D, Andres A, Gonzalez-Molina M, Oppenheimer F, et al. Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study. Nephrol Dial Transplant. 2012;27 Suppl 4:iv39–iv46.
Morard I, Mentha G, Spahr L, Majno P, Hadengue A, Huber O, et al. Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels. Clin Transplant. 2006;20(1):96–101.
Moreno-Borchart A. Building organs piece by piece. Accomplishments and future perspectives in tissue engineering. EMBO Rep. 2004;5:1025–8.
Morrissey PE, Monaco AP. Donation after circulatory death: current practices, ongoing challenges, and potential improvements. Transplantation. 2014;97:258–64.
Muramatsu M, Gonzalez HD, Cacciola R, Aikawa A, Yaqoob MM, Puliatti C. ABO incompatible renal transplants: Good or bad? World J Transplant. 2014;4:18–29.
Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326–33.
NHS Blood and Transplant. Organ Donation and Transplantation: Activity Report 2014-2015. Available from: http://nhsbtmediaservices.blob.core.windows.net/organ-donation-assets/pdfs/activity_report_2014_15.pdf (accessed June 2017).
NHS England. Renal Transplantation. 2013; Available from: https://www.england.nhs.uk/wp-content/uploads/2014/04/a07-renal-transpl-ad-0414.pdf. (accessed June 2017).
Nashan B. mTOR inhibition and clinical transplantation: liver. Transplantation. 2018;102(2S Suppl 1):S19–S26.
National Institute for Health and Care Excellence (NICE). Immunosuppressive therapy for renal transplantation in adults. NICE technology appraisal guidance [TA85]. September 2004; Available from: https://www.nice.org.uk/guidance/ta85 (accessed June 2017).
National Institute for Health and Care Excellence (NICE). Immunosuppressive therapy for renal transplantation in children and adolescents. NICE technology appraisal guidance [TA99]. April 2006; Available from: https://www.nice.org.uk/guidance/ta99 (accessed June 2017).
National Institute for Health and Care Excellence (NICE). Living-donor lung transplantation for end-stage lung disease. NICE interventional procedure guidance [IPG170]. May 2006; Available from: https://www.nice.org.uk/guidance/ipg170 (accessed June 2017).
National Institute for Health and Care Excellence (NICE). Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. NICE interventional procedure guidance [IPG257]. April 2008; Available from: https://www.nice.org.uk/guidance/ipg257 (accessed June 2017).
National Institute for Health and Care Excellence (NICE). Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. NICE interventional procedure guidance [IPG274]. September 2008; Available from: https://www.nice.org.uk/guidance/ipg274 (accessed June 2017).
National Institute for Health and Care Excellence (NICE). Corneal endothelial transplantation. NICE interventional procedure guidance [IPG304]. June 2009; Available from: https://www.nice.org.uk/guidance/ipg304 (accessed June 2017).
National Institute for Health and Care Excellence (NICE). Everolimus for preventing organ rejection in liver transplantation. NICE technology appraisal guidance [TA348]. July 2015; Available from: https://www.nice.org.uk/guidance/ta348 (accessed June 2017).
National Institute for Health and Care Excellence (NICE). Living-donor liver transplantation. NICE interventional procedure guidance [IPG535]. November 2015; Available from: https://www.nice.org.uk/guidance/ipg535 (accessed June 2017).
National Kidney Federation. Transplantation Cost Effectiveness. February 2010; Available from: http://www.kidney.org.uk/archives/news-archive-2/campaigns-transplantation-trans-cost-effect/ (accessed June 2017).
Nett PC, Heisey DM, Fernandez LA, Sollinger HW, Pirsch JD. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation. 2004;78:1036–41.
Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: The ‘ReSpECT’ Study. Am J Transplant. 2009;9: 327–36.
Nourbala MH, Hollisaaz MT, Nasiri M, Bahaeloo-Horeh S, Najafi M, Araghizadeh H, et al. Pain affects health-related quality of life in kidney transplant recipients. Transplant Proc. 2007;39:1126–9.
O'Connell PJ, Zhang W, Menon MC, Yi Z, Schröppel B, Gallon L, et al. Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet. 2016;388:983–93.
Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–40.
Ojo AO. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol. 2007;27:498–507.
Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:745–55.
Orens JB, Garrity ER Jr. General overview of lung transplantation and review of organ allocation. Proc Am Thorac Soc. 2009;6:13–9.
Organ Donation Taskforce. The Organ Donation Taskforce Implementation Programme’s Final Report, 2011. 2011; Available from: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/4249/theorgandonationtaskforcimplementationprogrammesfinalreport2011.pdf (accessed June 2017).
Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y et al. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. Under review
Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant. 2012;27:825–32.
Pascual J, Srinivas TR, Chadban S, Citterio F, Oppenheimer F, Tedesco H, et al. TRANS FORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation. Open Access Journal of Clinical Trials. 2014;6:45–54.
Pascual J, Zuckermann A, Djamali A, Hertig A, Naesens M. Rabbit antithymocyte globulin and donor-specific antibodies in kidney transplantation - A review. Transplant Rev (Orlando). 2016;30:85–91.
Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant. 2015;50:476–82.
Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016;51:786–92.
Penninga L, Møller CH, Gustafsson F, Gluud C, Steinbrüchel DA. Immunosuppressive T-cell antibody induction for heart transplant recipients. Cochrane Database Syst Rev. 2013a;12:CD008842.
Penninga L, Møller CH, Penninga EI, Iversen M, Gluud C, Steinbrüchel DA. Antibody induction therapy for lung transplant recipients. Cochrane Database Syst Rev. 2013b;11:CD008927.
Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients. Cochrane Database Syst Rev. 2014;6:CD010253.
Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus ciclosporin in recipients of extended criteria donor kidneys. Am J Transplant. 2012;12:630–9.
Pinson CW, Feurer ID, Payne JL, Wise PE, Shockley S, Speroff T. Health-related quality of life after different types of solid organ transplantation. Ann Surg. 2000 232:597–607.
Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, et al. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol. 2017;9:352–67.
Radtke J, Dietze N, Spetzler VN, Fischer L, Achilles EG, Li J, et al. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid. Transpl Infect Dis 2016;18:79–88.
Randleman JB, Song CD, Palay DA. Indications for and outcomes of penetrating keratoplasty performed by resident surgeons. Am J Ophthalmol. 2003;136:68–75.
Redfield RR, Scalea JR, Odorico JS. Simultaneous pancreas and kidney transplantation: current trends and future directions. Curr Opin Organ Transplant. 2015;20:94–102.
Report of the Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain Death. A Definition of Irreversible Coma. JAMA. 1968;205:337–340.
Rostaing L, Vincenti F, Grinyó J, Rice KM, Bresnahan B, Steinberg S, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant. 2013;13:2875–83.
Rummo OO, Carmellini M, Rostaing L, Oberbauer R, Christiaans MH, Mousson C, et al. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus. Transpl Int. 2017;30(1):83–95.
Sáez-Giménez B, Berastegui C, Loor K, López-Meseguer M, Monforte V, Bravo C, et al. Deep vein thrombosis and pulmonary embolism after solid organ transplantation: an unresolved problem. Transplant Rev (Orlando). 2015;29:85–92.
Sageshima J, Ciancio G, Chen L, Burke GW. Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation. Biologics. 2009;3:319–36.
Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant. 2013;13:1734–45.
Saliba F, Duvoux C, Gugenheim J, Kamar N, Dharancy S, Salamé E, et al. Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: A multicenter, randomized trial. Am J Transplant. 2017;17(7):1843–52.
Salis P, Caccamo C, Verzaro R, Gruttadauria S, Artero M. The role of basiliximab in the evolving renal transplantation immunosuppression protocol. Biologics. 2008;2:175–88.
Salvadori M, Bertoni E. Long-term outcome of everolimus treatment in transplant patients. Transpl Res Risk Management. 2011:3 77–90.
Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004;4:231–6.
Salvadori M, Rosso G, Bertoni E. Update on ischemia-reperfusion injury in kidney transplantation: Pathogenesis and treatment. World J Transplant. 2015;5:52–67.
Sayegh MH. Looking into the crystal ball: kidney transplantation in 2025. Nat Clin Pract Nephrol. 2009;5:117.
Schnitzler MA, Skeans MA, Axelrod DA, Lentine KL, Randall HB, Snyder JJ, et al. OPTN/SRTR 2015 Annual Data Report: Economics. Am J Transplant. 2017;17 Suppl 1:425–502.
Segev DL, Muzaale AD, Caffo BS, Mehta SH, Singer AL, Taranto SE, et al. Perioperative mortality and long-term survival following live kidney donation. JAMA. 2010;303:959–66.
Shapiro AMJ, Ricordi C. Chapter 61. Islet Cell Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 682–90. 2014; Wiley Online Library.
Shrestha B, Haylor J, Raftery A. Historical perspectives in kidney transplantation: an updated review. Prog Transplant. 2015;25(1):64–9.
Singh D, Taylor DO. Advances in the understanding and management of heart transplantation. F1000Prime Rep. 2015;7:52.
Singh S, Watt KD. Long-term medical management of the liver transplant recipient: what the primary care physician needs to know. Mayo Clin Proc. 2012;87:779–90.
Smith JM, Skeans MA, Horslen SP, Edwards EB, Harper AM, Snyder JJ, et al. OPTN/SRTR 2015 Annual Data Report: Intestine. Am J Transplant. 2017;17 Suppl 1:252–285.
Squires RH, Ng V, Romero R, Ekong U, Hardikar W, Emre S, et al. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Hepatology. 2014;60:362–98.
Steering Committee of the Istanbul Summit. Organ trafficking and transplant tourism and commercialism: the Declaration of Istanbul. Lancet. 2008;372:5–6.
Stegall MD, Cornell LD, Park WD, Smith BH, Cosio FG. Renal allograft histology at 10 years after transplantation in the tacrolimus era: evidence of pervasive chronic injury. Am J Transplant. 2018;18: 180–8.
Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi ZM. The outcomes of adult liver transplants in the United States from 1987 to 2013. Liver Int. 2015;35(8):2036–41.
Sterneck M, Kaiser GM,, Heyne N, Richter N, Rauchfuss F, Pascher A, et al. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study. Clin Transplant. 2016;30:741–8.
Tabar V, Studer L. Pluripotent stem cells in regenerative medicine: challenges and recent progress. Nat Rev Genet. 2014;15:82–92.
Taguchi A, Kaku Y, Ohmori T, Sharmin S, Ogawa M, Sasaki H, et al. Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. Cell Stem Cell. 2014;14:53–67.
Takahashi K, Uchida K, Yoshimura N, Takahara S, Teraoka S, Teshima R, et al. Efficacy and safety of concentration-controlled everolimus with reduced-dose ciclosporin in Japanese de novo renal transplant patients: 12-month results. Transplant Res 2013;2:14.
Tan DT, Dart JK, Holland EJ, Kinoshita S. Corneal transplantation. Lancet. 2012;379:1749–61.
Teperman L, Moonka D, Sebastian A, Sher L, Marotta P, Marsh C, et al. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl. 2013;19:675–89.
Thomusch O, Wiesener M, Opgenoorth M, Pascher A, Woitas RP, Witzke O, et al. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Lancet. 2016;388:3006–16.
Tso PL, Pearson TC. Chapter 55. Kidney Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 617–30. 2014; Wiley Online Library.
Tedesco Silva H Jr, Cibrik D, Johnston T, Lackova E, Mange K, Panis C, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant. 2010;10:1401–13.
Tonsho M, Michel S, Ahmed Z, Alessandrini A, Madsen JC. Heart transplantation: challenges facing the field. Cold Spring Harb Perspect Med. 2014;4. pii:a015636.
United Network for Organ Sharing (UNOS). Transplants By Organ Type January 1, 1988 - January 31, 2016. 2016; Available from: https://www.unos.org/data/ (accessed June 2017).
United Network for Organ Sharing (UNOS). Policy brochures. 2015; Available from: https://www.unos.org/policy/policy-brochures/(accessed June 2017).
United States Renal Data System (USRDS). 2015 Annual Data Report. 2015; Available from: https://www.usrds.org/2015/view/ (accessed June 2017).
US Department of Health and Human Services. Organ Procurement and Transplant Network Annual Data Report 2012. Published June 2014. Available from: https://srtr.transplant.hrsa.gov/annual_reports/2012/pdf/2012_SRTR_ADR_updated_full_intro.pdf accessed March 2018.
Valapour M, Skeans MA, Smith JM, Edwards LB, Cherikh WS, Uccellini K, et al. OPTN/SRTR 2015 Annual Data Report: Lung. Am J Transplant. 2017;17 Suppl 1:357–424.
Ventura-Aguiar P, Campistol JM, Diekmann F. Safety of mTOR inhibitors in adult solid organ transplantation. Expert Opin Drug Saf. 2016;15:303–19.
Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus ciclosporin in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10:535–46.
Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374:333–43.
Wagner M, Earley AK, Webster AC, Schmid CH, Balk EM, Uhlig K. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2015;12:CD007746.
Watson CL, Mahe MM, Múnera J, Howell JC, Sundaram N, Poling HM, et al. An in vivo model of human small intestine using pluripotent stem cells. Nat Med. 2014;20:1310–4.
Watson CJ, Dark JH. Organ transplantation: historical perspective and current practice. Br J Anaesth. 2012;108 Suppl 1:i29–42.
Wei TY, Chiang YJ, Hsieh CY, Weng LC, Lin SC, Lin MH. Health related quality of life of long-term kidney transplantation recipients. Biomed J. 2013;36:243–51.
Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1–15.
Weiss DJ. Current status of stem cells and regenerative medicine in lung biology and diseases. Stem Cells. 2014;32:16–25.
Xie X, Jiang Y, Lai X, Xiang S, Shou Z, Chen J. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis. BMC Nephrol. 2015;16:91.
Xu DW, Wan P, Xia Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. World J Gastroenterol. 2016;22:3325–34.
Yokote S, Matsunari H, Iwai S, Yamanaka S, Uchikura A, Fujimoto E, et al. Urine excretion strategy for stem cell-generated embryonic kidneys. Proc Natl Acad Sci USA. 2015;112:12980–5.
Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015;34:1264–77.
Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstädt H, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury. JAMA. 2016;315(20):2190–9.
Zavras N, Misiakos E, Konstantinos V, Salakos C. Short-bowel syndrome in children — an update in management strategies. Chapter 8. In: Pediatric Nursing, Psychiatric and Surgical Issues. Ozdemir O (ed.). 2015; InTech (online), available from https://www.intechopen.com/books/pediatric-nursing-psychiatric-and-surgical-issues/short-bowel-syndrome-in-children-an-update-in-management-strategies (accessed June 2017).
Zhang X. Direct anti-HCV agents. Acta Pharm Sin B. 2016;6:26–31.
Zhao DQ, Li SW, Sun QQ. Sirolimus-Based Immunosuppressive Regimens in Renal Transplantation: A Systemic Review. Transplant Proc. 2016;48:3–9.
Alternatively login via
Back to epgonline.org